Immix Biopharma(US:IMMX)2026-03-25 21:19Financial Performance - Immix Biopharma, Inc. reported general and administrative expenses of $13,697,817 for the year ended December 31, 2025, an increase from $11,381,978 in 2024, primarily due to higher employee compensation and professional services costs [358][359]. - Research and development expenses rose to $16,258,598 in 2025 from $11,292,702 in 2024, driven by costs associated with ongoing clinical trials and increased spending funded by share offerings totaling net proceeds of $107,349,347 [360][361]. - Interest income decreased to $555,526 in 2025 from $1,017,354 in 2024, attributed to lower balances in money market funds [362]. - Net cash used in operating activities for the year ended December 31, 2025 was $23,930,304, primarily due to a net loss of $29,438,613 [379]. - Net cash provided by financing activities was $107,386,859 for the year ended December 31, 2025, primarily from the sale of common stock [381]. - Net cash used in investing activities was $7,213,785 for the year ended December 31, 2025, primarily for short-term investments [380]. - The company recorded stock-based compensation expense of $2,441,875 for the year ended December 31, 2025 [379]. Funding and Capital - The company received approximately $6.2 million in grant reimbursements from the California Institute for Regenerative Medicine (CIRM) as part of an $8 million grant awarded to support the clinical development of NXC-201 [367]. - Immix Biopharma conducted an underwritten public offering in December 2025, selling 19,117,646 shares at $5.10 per share, resulting in net proceeds of approximately $93.7 million after underwriting discounts [371]. - The company completed a private placement in September 2025, raising approximately $9.3 million from the sale of 3,915,604 shares and warrants [370]. - The company entered into an At The Market Offering Agreement in June 2025, allowing for the sale of up to $50 million in shares, with net proceeds of $4,409,430 from sales in 2025 [369]. - The company anticipates needing additional capital beyond the next 12 months to continue planned operations [373]. Operational Expenses - Immix Biopharma's primary cash usage is for operating expenses, including clinical research and development, with expectations of increased expenses as clinical programs expand [365]. - The company expects to incur significant commercialization expenses if marketing approval is obtained for any product candidates [372]. - The company has committed to funding NXC-201 clinical trials in Israel with an estimated total cost of approximately $13 million over four years [353]. - The company entered into a long-term operating lease agreement for biopharmaceutical manufacturing space with total lease payments expected to be $1.4 million through December 2033 [377]. - The company has no long-term manufacturing and supply agreements but enters into contracts on an as-needed basis [378]. Strategic Considerations - The company has incurred significant net losses since inception and does not expect to generate revenue until regulatory approval and commercialization of its product candidates [364]. - The company may need to relinquish valuable rights to technologies or revenue streams if additional funds are raised through collaborations or strategic alliances [374]. - As of December 31, 2025, the company had total assets of approximately $104.8 million and working capital of approximately $91.1 million [373].